{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T03:40:31Z","timestamp":1775706031495,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ymgme.2018.02.011","type":"journal-article","created":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T12:31:23Z","timestamp":1519043483000},"page":"479-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002\/MOR-100), representing 5\u202fyears of treatment"],"prefix":"10.1016","volume":"123","author":[{"given":"Christian","family":"Hendriksz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saikat","family":"Santra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarekegn","family":"Geberhiwot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Jesaitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara M.","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celeste","family":"Decker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.02.011_bb0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ymgme.2014.10.015","article-title":"Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome","volume":"114","author":"Harmatz","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","article-title":"The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects","volume":"109","author":"Harmatz","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.04.002","article-title":"Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA","volume":"110","author":"Hendriksz","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ymgme.2016.05.018","article-title":"Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome","volume":"119","author":"Hendriksz","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10545-016-9973-6","article-title":"Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome","volume":"39","author":"Hendriksz","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0030","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0035","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40262-014-0173-y","article-title":"Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome","volume":"53","author":"Qi","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0045","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2018.02.011_bb0050","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2014second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network Symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0055","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.clinthera.2014.11.005","article-title":"Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, a phase III trial","volume":"37","author":"Schweighardt","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","article-title":"International Morquio A Registry: clinical manifestation and natural course of Morquio A disease","volume":"30","author":"Monta\u00f1o","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2016.11.017","article-title":"Long-term immunogenicity of elosulfase alfa in the treatment of Morquio A syndrome: results from MOR-005, a phase III extension study","volume":"39","author":"Long","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-9-32","article-title":"Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey","volume":"9","author":"Hendriksz","year":"2014","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0075","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/ajmg.a.37172","article-title":"Safety and physiological effects of two different doses of elosulfase alfa in patients with Morquio A syndrome: a randomized, double-blind, pilot study","volume":"167","author":"Burton","year":"2015","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0080","article-title":"Phase 1\/2 pharmacokinetic studies of recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) in MPS IVA patients","author":"Qi","year":"2012"},{"key":"10.1016\/j.ymgme.2018.02.011_bb0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jim.2016.10.006","article-title":"Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome","volume":"440","author":"Melton","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ymgme.2018.02.011_bb0090","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10897-013-9579-1","article-title":"Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families","volume":"22","author":"Freedman","year":"2013","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ymgme.2018.02.011_bb0095","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ymgme.2009.04.007","article-title":"Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses","volume":"97","author":"Burton","year":"2009","journal-title":"Mol. Genet. Metab."},{"issue":"1384","key":"10.1016\/j.ymgme.2018.02.011_bb0100","first-page":"1386","article-title":"Home therapy for lysosomal storage disorders","volume":"16","author":"Hughes","year":"2007","journal-title":"Br. J. Nurs."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218300684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218300684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T02:39:53Z","timestamp":1565318393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218300684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1096719218300684"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.011","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002\/MOR-100), representing 5\u202fyears of treatment","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}